跳至主要内容
临床试验/CTRI/2021/08/035334
CTRI/2021/08/035334尚未招募3 期

A prospective community based study for the evaluation of Rajapravartani Vati in the Management of Primary Dysmenorrhoea

Central Council for Research in Ayurvedic Sciences CCRAS10 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年4月8日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
50
试验地点
10
主要终点
i.Change in Visual Analog Scale (VAS) for pain.

研究概览

简要总结

The study is a prospective community based study for the evaluation of clinical effects of Rajapravartani vati in the management of Primary Dysmenorrhoea. It is a single arm trial with a sample size of 50 at each partcipating center (total 10 CCRAS centers). The outcome measures are VAS Score and WaLLIDD score.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 25.00 Year(s)(—)
性别
Female

入选标准

  • i.Young women of age 18 -25 years of scheduled Caste community ii.Self-reported history consistent with primary dysmenorrheal of moderate to severe nature (Mild: doesn’t interfere in normal activities, Moderate: slightly interferes in daily routines but can be managed by painkillers, Severe: markedly prevents daily life activities) with a self-reported menstrual cycle of averaging 21-35 days.
  • iii.Willing and able to participate in the study (Written informed consent or assent).

排除标准

  • i.Irregular Cycles.
  • ii.Cases of secondary Dysmenorrhea iii.Pain abdomen associated with excessive bleeding per vagina.
  • iv.Presence of persistent pelvic pain throughout the menstrual cycle.
  • v.Known case / diagnosis /h/o of leiomyoma of uterus, ovarian cyst, endometriosis.
  • vi.Associated with clinically diagnosed pelvic inflammatory disease (PID), vii.Associated with any pre-diagnosed or clinically diagnosed systemic disorders likely to influence menstrual cycle.
  • viii.Patients with Hb ≤ 7 gm % ix.History of malignancy of pelvic organs.
  • x.Diagnosed cases Hypo/hyperthyroidism.
  • xi.Woman using IUD / Oral Contraceptive Pills (OCP) xii.Patient co morbid with systemic diseases like diabetes mellitus, hypertension, cardiac/ Renal/ Pulmonary/ Hepatic disorders.
  • xiii.Women who are planning to conceive in the next 6 months.
  • xiv.Participation in other concomitant therapy for acute or chronic pain.

结局指标

主要结局

i.Change in Visual Analog Scale (VAS) for pain.

时间窗: At baseline, after 1 month, after 2 months, after 3 months and after 4 months.

次要结局

  • i.Changes in total WaLLID score.(ii.Change in Hb status of the subject from the baseline to the end of trial -12 weeks.)

研究者

发起方
Central Council for Research in Ayurvedic Sciences CCRAS
申办方类型
Government funding agency

研究点 (10)

Loading locations...

相似试验